NCT00481260

Brief Summary

Hgb C is an hemoglobinopathy quite rare in Israel. The clinical status of patients that are diagnosed as homozygous to this disease is quite benign but not study in large groups. Also the characteristics of carriers and the incidence in northern Israel were a large arab population lives, was not study. The results of this study can be useful for screening purpose in a area were another hemoglobinopathies are frequent.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started May 2007

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2007

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

May 31, 2007

Completed
1 day until next milestone

First Posted

Study publicly available on registry

June 1, 2007

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2008

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2008

Completed
Last Updated

September 4, 2009

Status Verified

September 1, 2009

Enrollment Period

1.6 years

First QC Date

May 31, 2007

Last Update Submit

September 3, 2009

Conditions

Hgb C Hemoglobinopathy

Keywords

Hgb CScreening

Interventions

Medical history and basic laboratory analysisPROCEDURE

Medical history and basic laboratory analysis

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients diagnosed at the pediatric Hematology Unit of laboratory data from the thalassemia screening in northern Israel

You may qualify if:

  • All patients diagnosed as homozygous for Hgb C disease or double heterozygous in combination to other abnormal hemoglobin, and all the carriers detected in the hematology laboratory during the screening for abnormal hemoglobins in northern Israel

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Pediatric Hematology Unit - HaEmek Medical Center

Afula, 18101, Israel

Location

MeSH Terms

Interventions

Health Records, Personal

Intervention Hierarchy (Ancestors)

Medical RecordsRecordsData CollectionEpidemiologic MethodsInvestigative Techniques

Study Officials

  • Ariel Koren, MD

    Pediatric Hematology Unit, Ha'Emek Medical Center

    STUDY DIRECTOR

  • luci Zalman, Phd

    Hematology Laboratory - HaeEmek Medical Center

    STUDY CHAIR

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER

Study Record Dates

First Submitted

May 31, 2007

First Posted

June 1, 2007

Study Start

May 1, 2007

Primary Completion

December 1, 2008

Study Completion

December 1, 2008

Last Updated

September 4, 2009

Record last verified: 2009-09

Locations

IL(1)